Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

W. Ray Kim, Thomas Berg, Tarik Asselah, Robert Flisiak, Scott Fung, Stuart C. Gordon, Harry L A Janssen, Pietro Lampertico, Daryl Lau, Jeffrey D. Bornstein, Raul E Aguilar Schall, Phillip Dinh, Leland J. Yee, Eduardo B. Martins, Seng Gee Lim, Rohit Loomba, Jörg Petersen, Maria Buti, Patrick Marcellin

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Abstract

Background & Aims: While the gold standard in the assessment of liver fibrosis remains liver biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB). This study aimed to evaluate the performance of two commonly used non-invasive scoring systems (aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4)) to predict fibrosis stage in CHB patients. Materials and methods: Demographic, histologic and clinical laboratory data from two trials investigating tenofovir disoproxil fumarate in CHB were analyzed. Predicted fibrosis stage, based on established scales and cut-off values for APRI and FIB-4 scores, was compared with Ishak scores obtained from liver biopsy at baseline and at 240. week follow-up. Results: In the 575 patients with a baseline liver biopsy, APRI and FIB-4 scores correlated with Ishak stage (p

Original languageEnglish (US)
JournalJournal of Hepatology
DOIs
StateAccepted/In press - May 21 2015
Externally publishedYes

Keywords

  • APRI
  • Chronic hepatitis B
  • FIB-4
  • Fibrosis

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients'. Together they form a unique fingerprint.

Cite this